Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Diprivan Anti-Generic Promos Require Corrective Letter - FDA

Executive Summary

AstraZeneca must issue a "Dear Healthcare Provider" letter clarifying misleading information regarding generic propofol found in its promotional materials for the anesthetic Diprivan, an FDA warning letter states.

You may also be interested in...



Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate

FDA’s Office of Prescription Drug Promotion objected to economic claims that the product could reduce ESA use in part because they were based on a subset of the approved population.

AstraZeneca Diprivan Pediatric ICU Sedation Safety Study Requested By FDA

AstraZeneca is planning an additional study of Diprivan for pediatric ICU sedation after finding an increased rate of mortality with the injectable anesthetic in a trial seeking the indication.

AstraZeneca Diprivan Pediatric ICU Sedation Safety Study Requested By FDA

AstraZeneca is planning an additional study of Diprivan for pediatric ICU sedation after finding an increased rate of mortality with the injectable anesthetic in a trial seeking the indication.

Related Content

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel